CD274 and cancer: From this perspective, the purpose of current combination therapies adopted to overcome drug resistance against PD-1/PD-L1 inhibitors can be considered as strategies to enhance the factors contributing to anti-cancer immunity by increasing the expression of neoantigens and further activation of T cells, as well as to diminish unfavorable factors by regulating suppressive immune cells and chemokines.